GC基因组的人工血液测试以90%的精确度检测直肠癌,并正在扩大至2026年对10种癌症进行筛查。 GC Genome's AI blood test detects colorectal cancer with 90% accuracy and is expanding to screen for 10 cancers by 2026.

根据《美国胃肠病学杂志》公布的一项研究,GC基因组的AI-动力血液测试Ai-CANCERCH显示,90.4%对检测直肠癌具有敏感性,94.7%对健康的个体具有特异性。 GC Genome's AI-powered blood test, ai-CANCERCH, demonstrated 90.4% sensitivity for detecting colorectal cancer and 94.7% specificity in healthy individuals, according to a study published in the American Journal of Gastroenterology. 测试采用低覆盖率的全基因测序和碎片组学方法,检测到百分之百的四级癌症和90%的早期可治疗性损伤,在年龄、肿瘤位置和腺瘤类型方面结果一致。 The test, using low-coverage whole-genome sequencing and fragmentomics, detected 100% of stage IV cancers and 90% of early-stage treatable lesions, with consistent results across age, tumor location, and adenoma type. 它还确定了58.3%的高级腺瘤。 It also identified 58.3% of advanced adenomas. 非侵入性试验于2023年发射,只需要10毫升的血液,并将在2026年1月前扩大到检测10种癌症。 The non-invasive test, launched in 2023, requires only 10 mL of blood and is set to expand to detect 10 cancers by January 2026.